首頁 > 市場調查報告書 > 製藥

癌症

市場調查報告書

商品編碼

1471980

子宮頸癌治療市場規模和預測、全球和地區佔有率、趨勢和成長機會分析報告範圍：按類型、產品、最終用戶和地理位置

Cervical Cancer Treatment Market Size and Forecasts, Global and Regional Share, Trend, and Growth Opportunity Analysis Report Coverage: By Type, Product, End User, and Geography

出版日期: 2024年03月01日 | 出版商:

The Insight Partners | 英文 150 Pages | 商品交期: 1-5個工作天內

價格

簡介目錄

子宮頸癌治療市場預計將從2022年的94.3億美元成長到2030年的140.7億美元；預計2022年至2030年複合年成長率為5.13%。

子宮頸癌是指發生在子宮頸細胞（即連接陰道的子宮下部）的癌症。 90%的子宮頸惡性腫瘤是由於HPV感染引起的，並透過抹片篩檢確診。子宮頸癌盛行率的增加和HPV感染的增加是推動子宮頸癌治療市場成長的關鍵因素。然而，對診斷和治療方法缺乏認知阻礙了市場的成長。子宮頸癌治療市場趨勢包括主要參與者在子宮頸癌診斷和子宮頸癌治療藥物方面的強勁研發。

子宮頸癌盛行率的增加推動了子宮頸癌治療市場的成長。

癌症已成為全球主要死亡原因。根據世界衛生組織（WHO）的資料，2019年，癌症是全球183個國家70歲以下人口的第一大死因，也是全球123個國家的第四大死因。衛生組織2021 年3 月稱，2020 年約有1,000 萬人因不同癌症類型死亡。正在考慮的市場已顯示出顯著擴張，這可能與全球女性子宮頸癌發生率上升有關。根據世界衛生組織 (WHO) 統計，子宮頸癌每年奪走超過 27 萬名女性的生命。由於子宮頸癌發現較晚，較貧窮國家的子宮頸癌死亡率較高。由於用於早期發現子宮頸癌的子宮頸癌診斷測試的接受度不斷提高，預計該市場將會成長。

子宮頸癌盛行率的不斷上升給世界各地的醫療保健系統帶來了負擔。據國際癌症研究機構 (IARC) 稱，到 2040 年，全球新發癌症病例負擔預計將達到約 2,750 萬例，到該年該疾病可能會導致約 1.63 億人死亡。生活方式的改變、吸煙、體力活動減少以及不確定的健康和氣候條件等因素可能會在未來幾年給世界帶來更大的癌症負擔。因此，控制和預防全球範圍內不斷增加的癌症至關重要。

各國政府已啟動了加強癌症治療和預防措施的計畫和措施。例如，2017 年，世界衛生大會批准了癌症決議 (WHA70.12)，這是預防和控制癌症的綜合方法。該計畫一直呼籲世界衛生組織和各國政府加緊努力，實現《預防和控制非傳染性疾病（NCD）全球行動計畫（2013-2020）》以及《2030 年聯合國永續發展目標》中規定的目標。癌症早期死亡的永續發展議程。此外，各種民間組織也加入了防止癌症負擔日益增加的行動計劃，這產生了對更好的疾病預防措施的需求。因此，子宮頸癌盛行率的不斷上升加速了對新有效治療方法（例如新抗原）的需求，從而推動了市場的成長。

人口、醫療保健提供者和政策制定者對子宮頸癌缺乏認知，獲得高品質醫療保健服務和子宮頸篩檢計劃的機會有限，以及缺乏功能性轉診系統是導致子宮頸癌高發病率和死亡率的因素。由於細胞學篩檢和早期子宮頸病變快速治療的普及，工業化國家的子宮頸癌發病率和死亡率有所下降。實施基於人群的子宮頸篩檢並提高低收入和中等收入國家 (LMIC) 的接受度對於降低子宮頸癌死亡率至關重要。提高對危險因子的認知，例如年輕時第一次性交和多位男性性伴侶；與 HPV 8、9 和 10 型相關的高風險；年輕時第一次足月懷孕；長期使用口服避孕藥；愛滋病毒感染可能有助於提高篩檢計畫的參與度。更了解子宮頸癌的症狀，如經間期陰道出血、停經後陰道出血、性交後陰道出血、陰道分泌物惡臭和下腹疼痛，可能有助於女性儘早尋求幫助。然而，人們對子宮頸癌缺乏認知阻礙了子宮頸癌治療市場的成長。

子宮頸癌治療市場分析是根據類型、產品和最終用戶考慮以下細分市場進行的。依類型，市場分為鱗狀細胞癌、腺鱗癌和腺癌。根據產品，市場分為手術、放射治療、化療、免疫療法和治療性疫苗。依最終用戶分類，市場分為醫院、家庭護理、癌症中心等。子宮頸癌治療市場報告的地理範圍包括北美（美國、加拿大和墨西哥）、歐洲（英國、德國、法國、義大利、西班牙和歐洲其他地區）、亞太地區（中國、日本、印度、澳洲、韓國和亞太其他地區）、中東和非洲（阿拉伯聯合大公國、沙烏地阿拉伯、南非以及中東和非洲其他地區）以及南美洲和中美洲（巴西、阿根廷、以及南美洲和中美洲的其他地區）。 2022年，北美佔據最大的子宮頸癌治療市場。

根據地理位置，子宮頸癌治療市場分為北美、歐洲、亞太地區、中東和非洲以及南美洲和中美洲。

2022年，北美在子宮頸癌治療市場中佔據最大佔有率，其中美國佔據了很大的市場佔有率。大量的研發活動主要推動了該國市場的成長；政府、其他私營和非私營組織的財政援助、製藥和技術公司內部的合作以及該國神經系統疾病的盛行率不斷上升。此外，政府組織在加強測試程序方面的積極參與預計將在預測期內提振市場。此外，罕見疾病監管政策的實施可能為預測期內的市場成長提供重大機會。例如，美國癌症協會（ACS）於2020年9月更新了子宮頸癌篩檢指南。因此，這種積極參與的組織預計將支持市場成長。此外，透過識別和評估不同地區市場的主要參與者來進行子宮頸癌治療市場分析。癌治療市場報告。

歐洲
- 德國
- 法國
- 義大利
- 西班牙
- 英國
- 歐洲其他地區
亞太
- 澳洲
- 中國
- 印度
- 日本
- 韓國
- 亞太其他地區
中東和非洲
- 南非
- 沙烏地阿拉伯
- 阿拉伯聯合大公國
- 中東和非洲其他地區
南美洲和中美洲
- 巴西
- 阿根廷
- 南美洲和中美洲其他地區

第 11 章：產業格局

併購
協議、合作、合資企業
新產品發布
擴張和其他策略發展

第 12 章：競爭格局

關鍵參與者的熱圖分析
公司定位與專注

第 13 章：子宮頸癌治療市場 - 主要公司概況

F. Hoffmann-La Roche Ltd
Merck Sharp and Dohme Corp.
GlaxoSmithKline plc.
Genentech, Inc.
Amgen Inc.
Advaxis, Inc.
Biocon
Allergan, Inc
Pfizer Inc
AstraZeneca

第 14 章：附錄

簡介目錄

Product Code: TIPRE00004058

The cervical cancer treatment market is expected to grow from US$ 9.43 billion in 2022 to US$ 14.07 billion by 2030; it is anticipated to record a CAGR of 5.13% from 2022 to 2030.

Cervical cancer refers to the cancer that occurs in the cells of the cervix i.e. the lower part of the uterus that connects to the vagina. In 90% of the cases, cervical malignancies occur due to the HPV infection and are diagnosed through smear screening. The increasing prevalence of cervical cancer and the rise in HPV infections are the key factors driving the cervical cancer treatment market growth. However, the lack of awareness about the diagnosis and treatment methods hampers the market's growth. Cervical cancer treatment market trends include the strong R&D from key players for cervical cancer diagnosis and drugs in cervical cancer treatment.

Increasing Prevalence of Cervical Cancer Fuel Cervical Cancer Treatment Market Growth.

Cancer has emerged as a leading cause of death worldwide. According to the World Health Organization (WHO), cancer was the first leading cause of death in people of age below 70 years in 183 countries and the fourth leading cause of death in 123 countries worldwide in 2019. In addition, according to data published by the WHO in March 2021, ~10 million deaths occurred in 2020 due to different cancer types. The market under consideration has shown significant expansion, which can be linked to the rising frequency of cervical cancer among women worldwide. According to the World Health Organization (WHO), cervical cancer kills more than 270,000 women each year. Cervical cancer mortality rates are greater in poorer nations due to the late discovery of the disease. The market is predicted to rise due to the increasing acceptance of cervical cancer diagnostic tests for the early detection of cervical cancer.

The increasing prevalence of cervical cancer has created a burden on the healthcare systems across the world. According to the International Agency for Research on Cancer (IARC), the global burden of new cancer cases is estimated to reach ~ 27.5 million by 2040, and the disease is likely to be a cause of ~163 million deaths by that year. Factors such as lifestyle changes, smoking, reduced physical activities, and uncertain health and climatic conditions are likely to lead to an even greater burden of cancer in the world in the coming years. Therefore, controlling and preventing the increasing number of cancers worldwide is essential.

Various governments have initiated programs and initiatives to increase cancer treatment and preventive measures. For instance 2017, the World Health Assembly approved the Resolution Cancer (WHA70.12), an integrated approach to preventing and controlling cancer. The program has been appealing to the WHO and various governments to accelerate their efforts to achieve the targets that are specified in the Global Action Plan (2013-2020) for the prevention and control of noncommunicable diseases (NCDs) as well as in the 2030 UN Agenda for Sustainable Development to reduce early deaths from cancer. In addition, various private organizations have joined the action plans to prevent the increasing burden of cancer, which is creating a demand for better preventive measures against the disease. Thus, the increasing prevalence of cervical cancer has accelerated the demand for new and effective therapeutic approaches, such as neoantigens, which is boosting the growth of the market.

The lack of awareness about cervical cancer among populations, healthcare providers, and policymakers, limited access to high-quality healthcare services and cervical screening programs, and a lack of functional referral systems are among the factors leading to the high incidence and mortality from cervical cancer. Cervical cancer incidence and mortality have lowered in industrialized countries owing to improved access to cytological screening and rapid treatment of early cervical lesions. It is critical to implement population-based cervical screening and increase its acceptance in low- and middle-income countries (LMICs) to reduce cervical cancer mortality. Raising awareness about risk factors such as first sexual intercourse at a young age and having multiple male sexual partners; high risk associated with the HPV types 8, 9, and 10; first full-term pregnancy at a young age; prolonged use of oral contraceptives; and HIV infections may help boost participation in screening programs. Better awareness regarding the symptoms of cervical cancer, such as intermenstrual vaginal bleeding, postmenopausal vaginal bleeding, post-coital vaginal bleeding, foul vaginal discharge, and lower abdomen pain, might help women seek early help. Nevertheless, the lack of awareness about cervical cancer among populations hinders the cervical cancer treatment market growth.

The cervical cancer treatment market analysis has been conducted by considering the following segments based on type, product, and end user. By type, the market is classified into squamous cell carcinoma, adenosquamous carcinoma, and adenocarcinoma. Based on product, the market is divided into surgery, radiation therapy, chemotherapy, immunotherapy, and therapeutic vaccines. By end user, the market is segmented into hospitals, home care, cancer centers, and others. The geographic scope of the cervical cancer treatment market report includes North America (the US, Canada, and Mexico), Europe (the UK, Germany, France, Italy, Spain, and the Rest of Europe), Asia Pacific (China, Japan, India, Australia, South Korea, and the Rest of Asia Pacific), the Middle East & Africa (the UAE, Saudi Arabia, South Africa, and the Rest of Middle East & Africa), and South & Central America (Brazil, Argentina, and the Rest of South & Central America). In 2022, North America held the largest cervical cancer treatment market share.

Based on geography, the cervical cancer treatment market is classified into North America, Europe, Asia Pacific, Middle East & Africa, and South & Central America.

North America held the largest share of the cervical cancer treatment market in 2022, In North America, the US holds a significant share of the market. A vast number of R&D activities primarily drives the market's growth in the country; financial aids by governments other private and non-private organizations, collaborations within pharmaceuticals and technology companies, and increasing prevalence of neurological diseases in the country. Additionally, increasing the active participation of the government organizations in enhancing the testing procedures is expected to boost the market during the forecast period. Furthermore, the implementation of regulatory policies for rare diseases is likely to offer a significant opportunity for the market's growth during the forecast period. For instance, the American Cancer Society (ACS) in September 2020 updated the guidelines for cervical cancer screening. Thus such active involvement organization is expected to support the market growth. Furthermore, the cervical cancer treatment market analysis is carried out by identifying and evaluating key players in the market across different regions.Centers for Disease Control and Prevention (CDC) and Food and Drug Administration (FDA) are key primary and secondary sources referred to while preparing the cervical cancer treatment market report.

1. Introduction

1.1 Scope of the Study
1.2 Market Definition, Assumptions and Limitations
1.3 Market Segmentation

2. Executive Summary

2.1 Key Insights
2.2 Market Attractiveness Analysis

3. Research Methodology

4. Cervical Cancer Treatment Market Landscape

4.1 Overview
4.2 PEST Analysis
4.3 Ecosystem Analysis
- 4.3.1 List of Vendors in the Value Chain

5. Cervical Cancer Treatment Market - Key Market Dynamics

5.1 Key Market Drivers
5.2 Key Market Restraints
5.3 Key Market Opportunities
5.4 Future Trends
5.5 Impact Analysis of Drivers and Restraints

6. Cervical Cancer Treatment Market - Global Market Analysis

6.1 Cervical Cancer Treatment - Global Market Overview
6.2 Cervical Cancer Treatment - Global Market and Forecast to 2030

7. Cervical Cancer Treatment Market - Revenue Analysis (USD Million) - By Type, 2020-2030

7.1 Overview
7.2 Adenocarcinoma
7.3 Adenosquamous carcinoma
7.4 Squamous cell carcinoma

8. Cervical Cancer Treatment Market - Revenue Analysis (USD Million) - By Product, 2020-2030

8.1 Overview
8.2 Gardasil/Gardasil 9
8.3 Cervarix
8.4 Avastin
8.5 Keytruda
8.6 Others

9. Cervical Cancer Treatment Market - Revenue Analysis (USD Million) - By Distribution Channel, 2020-2030

9.1 Overview
9.2 Hospital Pharmacies
9.3 Retail Pharmacies
9.4 Online Pharmacies

10. Cervical Cancer Treatment Market - Revenue Analysis (USD Million), 2020-2030 - Geographical Analysis

10.1 North America
- 10.1.1 North America Cervical Cancer Treatment Market Overview
- 10.1.2 North America Cervical Cancer Treatment Market Revenue and Forecasts to 2030
- 10.1.3 North America Cervical Cancer Treatment Market Revenue and Forecasts and Analysis - By Type
- 10.1.4 North America Cervical Cancer Treatment Market Revenue and Forecasts and Analysis - By Product
- 10.1.5 North America Cervical Cancer Treatment Market Revenue and Forecasts and Analysis - By Distribution Channel
- 10.1.6 North America Cervical Cancer Treatment Market Revenue and Forecasts and Analysis - By Countries
  - 10.1.6.1 United States Cervical Cancer Treatment Market
    - 10.1.6.1.1 United States Cervical Cancer Treatment Market, by Type
    - 10.1.6.1.2 United States Cervical Cancer Treatment Market, by Product
    - 10.1.6.1.3 United States Cervical Cancer Treatment Market, by Distribution Channel
  - 10.1.6.2 Canada Cervical Cancer Treatment Market
    - 10.1.6.2.1 Canada Cervical Cancer Treatment Market, by Type
    - 10.1.6.2.2 Canada Cervical Cancer Treatment Market, by Product
    - 10.1.6.2.3 Canada Cervical Cancer Treatment Market, by Distribution Channel
  - 10.1.6.3 Mexico Cervical Cancer Treatment Market
    - 10.1.6.3.1 Mexico Cervical Cancer Treatment Market, by Type
    - 10.1.6.3.2 Mexico Cervical Cancer Treatment Market, by Product
    - 10.1.6.3.3 Mexico Cervical Cancer Treatment Market, by Distribution Channel

Note - Similar analysis would be provided for below mentioned regions/countries

10.2 Europe
- 10.2.1 Germany
- 10.2.2 France
- 10.2.3 Italy
- 10.2.4 Spain
- 10.2.5 United Kingdom
- 10.2.6 Rest of Europe
10.3 Asia-Pacific
- 10.3.1 Australia
- 10.3.2 China
- 10.3.3 India
- 10.3.4 Japan
- 10.3.5 South Korea
- 10.3.6 Rest of Asia-Pacific
10.4 Middle East and Africa
- 10.4.1 South Africa
- 10.4.2 Saudi Arabia
- 10.4.3 U.A.E
- 10.4.4 Rest of Middle East and Africa
10.5 South and Central America
- 10.5.1 Brazil
- 10.5.2 Argentina
- 10.5.3 Rest of South and Central America

11. Industry Landscape

11.1 Mergers and Acquisitions
11.2 Agreements, Collaborations, Joint Ventures
11.3 New Product Launches
11.4 Expansions and Other Strategic Developments

12. Competitive Landscape

12.1 Heat Map Analysis by Key Players
12.2 Company Positioning and Concentration

13. Cervical Cancer Treatment Market - Key Company Profiles

13.1 F. Hoffmann-La Roche Ltd
- 13.1.1 Key Facts
- 13.1.2 Business Description
- 13.1.3 Products and Services
- 13.1.4 Financial Overview
- 13.1.5 SWOT Analysis
- 13.1.6 Key Developments

Note - Similar information would be provided for below list of companies